ArticleExperimental and therapeutic medicine2016
CXCR4 inhibitor attenuates ovalbumin-induced airway inflammation and hyperresponsiveness by inhibiting Th17 and Tc17 cell immune response.
Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM Syndrome.Journal of clinical immunology · 2026Trial
- Review
- Integrated bioinformatics and machine learning for shared diagnostic genes and mechanisms between periodontitis and psoriasis.Clinical rheumatology · 2026Article
- Exploratory investigation of changes in blood transcriptome following mepolizumab treatment for asthma.Frontiers in immunology · 2026Article
- CXCR4 inhibition alleviates prostatic inflammation and pelvic pain via suppressing Th17 cell differentiation and oxidative stress in EAP mice.International journal of biological sciences · 2026Article
- CXCL12 and CXCL13 as potential biomarkers for disease severity and recurrence in respiratory syncytial virus bronchiolitis.Scientific reports · 2025Article
- A Breath of Fresh Insight: Targeting CXCR4 in Early Chronic Obstructive Pulmonary Disease.American journal of respiratory cell and molecular biology · 2025Article
- Article
- Interleukin-17A Promotes Airway Remodeling in Chronic Obstructive Pulmonary Disease by Activating C-X-C Motif Chemokine Ligand 12 Secreted by Lung Fibroblasts.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Article
- Single-cell analysis of immune cells on gingiva-derived mesenchymal stem cells in experimental autoimmune uveitis.iScience · 2023Article
- Circular RNAs: emerging players in asthma and COPD.Frontiers in cell and developmental biology · 2023Review
- Sigma-1 Receptor Alleviates Airway Inflammation and Airway Remodeling Through AMPK/CXCR4 Signal Pathway.Inflammation · 2022Article
- CXC Chemokines in the Pathogenesis of Pulmonary Disease and Pharmacological Relevance.International journal of inflammation · 2022Review
- An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.Acta pharmaceutica Sinica. B · 2021Article
- Platelets Independently Recruit into Asthmatic Lungs and Models of Allergic Inflammation via CCR3.American journal of respiratory cell and molecular biology · 2021Article
- SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions.Molecular and cellular biochemistry · 2021Review
- The CXCR4/miR-125b/FoxP3 axis regulates the function of the epithelial barrier via autophagy in allergic rhinitis.American journal of translational research · 2020Article
- The Cell Research Trends of Asthma: A Stem Frequency Analysis of the Literature.Journal of healthcare engineering · 2018Article
- Relationship of Circulating CXCR4Aging and disease · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence suggests that chemokine (C-X-C motif) ligand 12 (CXCL12) and its receptor chemokine (C-X-C motif) receptor 4 (CXCR4) may contribute to the pathogenesis of allergic asthma. However, the underlying molecular mechanisms remain to be fully understood. T-helper 17 cells (Th17) and T-cytotoxic 17 cells (Tc17) have been implicated in the development of several allergic disorders, including asthma. The present study aimed to explore the association between CXCL12 signaling and Th17/Tc17 cells in the development of asthma. Ovalbumin (OVA)-sensitized BALB/c mice were treated with AMD3100, a specific CXCR4 antagonist, prior to OVA challenge. Following the final allergen (OVA) challenge, airway responsiveness to methacholine, influx of inflammatory cells to the airway, and cytokine levels in the bronchoalveolar lavage fluids (BALF) and lung homogenate were assessed. Interleukin (IL)-17-expressing CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.